analyzed serum samples from 286 prostate cancer patients and 68 individuals without malignant tumors, demonstrating that SPON2 exhibited superior predictive value compared to serum sarcosine, free PSA percentage ratio, and total PSA. This evidence concerns the gene KLK3 and prostate carcinoma.